scispace - formally typeset
V

Vincent C. O. Njar

Researcher at University of Maryland, Baltimore

Publications -  154
Citations -  10648

Vincent C. O. Njar is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Prostate cancer & Androgen receptor. The author has an hindex of 42, co-authored 146 publications receiving 9790 citations. Previous affiliations of Vincent C. O. Njar include Saarland University & University of Maryland Marlene and Stewart Greenebaum Cancer Center.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Regulation of androgen receptor activity by tyrosine phosphorylation

Zhiyong Guo, +15 more
- 01 Oct 2006 - 
TL;DR: It is reported that tyrosine phosphorylation of AR is induced by growth factors and elevated in hormone-refractory prostate tumors and such modification may be important for prostate tumor growth under androgen-depleted conditions.
Journal ArticleDOI

Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens: Synthesis, in Vitro Biological Activity, Pharmacokinetics, and Antitumor Activity in the LAPC4 Human Prostate Cancer Xenograft Model

Venkatesh D. Handratta, +10 more
- 25 Mar 2005 - 
TL;DR: To the authors' knowledge, this is the first example of an antihormonal agent (an inhibitor of androgen synthesis (CYP17 inhibitor)/antiandrogen) that is significantly more effective than castration in suppression of androgens-dependent prostate tumor growth.
Journal ArticleDOI

Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development.

Robert D. Bruno, +2 more
- 01 Aug 2007 - 
TL;DR: This review offers the first comprehensive analysis of strategies in drug development that either inhibit or exploit CYP enzymes for the treatment of cancer.
Journal ArticleDOI

CYP17 inhibitors for prostate cancer therapy

Tadas S. Vasaitis, +2 more
- 01 May 2011 - 
TL;DR: The role of androgen biosynthesis in the progression of prostate cancer and the impact of CYP17 inhibitors, such as ketoconazole, abiraterone acetate, VN/124-1 (TOK-001) and TAK-700 in the clinic and in clinical development are highlighted.